Ligand validation:8B3M

NXL: (2S,5R)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide

NXL is a Ligand Of Interest in 8B3M designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8B3M_NXL_A_301	68%	8%	0.122	0.933	2.81	1.81	6	6	2	0	100%	1
9ORH_NXL_B_301	100%	40%	0.034	0.99	0.47	1.85	-	4	1	0	100%	0.84
9ORS_NXL_B_301	100%	43%	0.038	0.987	0.49	1.69	-	2	0	0	100%	0.82
6MZ1_NXL_B_301	90%	50%	0.084	0.968	0.68	1.24	-	1	0	0	100%	1
9OR3_NXL_A_301	88%	41%	0.071	0.947	0.51	1.77	-	1	2	0	100%	0.9
9ORB_NXL_B_301	88%	37%	0.074	0.95	0.49	1.94	-	1	2	0	100%	0.81
4HBU_NXL_A_301	100%	51%	0.04	0.993	0.56	1.31	-	1	2	0	100%	1
9IL9_NXL_A_301	100%	20%	0.042	0.983	1.84	1.52	1	4	1	0	100%	1
9BZQ_NXL_A_401	99%	38%	0.059	0.986	1.51	0.93	1	-	0	0	100%	1
4S2I_NXL_B_301	96%	11%	0.06	0.97	2.33	1.82	3	4	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.